Mallinckrodt PLC (NYSE:MNK) has been assigned an average rating of “Hold” from the twenty-three ratings firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $41.96.
A number of equities analysts recently commented on the company. Mizuho reiterated a “neutral” rating and set a $21.00 price target (down previously from $22.00) on shares of Mallinckrodt in a report on Tuesday, January 9th. Canaccord Genuity set a $24.00 price target on Mallinckrodt and gave the stock a “hold” rating in a report on Sunday, January 7th. Cantor Fitzgerald set a $52.00 price target on Mallinckrodt and gave the stock a “buy” rating in a report on Monday, October 2nd. ValuEngine cut Mallinckrodt from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Morgan Stanley reduced their price target on Mallinckrodt from $40.00 to $27.00 and set an “equal weight” rating for the company in a report on Wednesday, November 8th.
Shares of Mallinckrodt (NYSE:MNK) opened at $21.30 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $2,020.00, a PE ratio of -1,065.00, a P/E/G ratio of 0.42 and a beta of 1.30. Mallinckrodt has a 12-month low of $19.00 and a 12-month high of $55.32.
In other news, VP Steven J. Romano acquired 2,000 shares of Mallinckrodt stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $21.96 per share, for a total transaction of $43,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Michael-Bryant Hicks acquired 7,900 shares of Mallinckrodt stock in a transaction dated Thursday, November 9th. The shares were purchased at an average price of $20.80 per share, with a total value of $164,320.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 30,460 shares of company stock valued at $659,486. Corporate insiders own 0.77% of the company’s stock.
Several large investors have recently modified their holdings of MNK. Schwab Charles Investment Management Inc. boosted its holdings in shares of Mallinckrodt by 9.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 405,655 shares of the company’s stock worth $18,178,000 after acquiring an additional 35,431 shares during the period. Schroder Investment Management Group boosted its holdings in shares of Mallinckrodt by 471.4% during the second quarter. Schroder Investment Management Group now owns 20,000 shares of the company’s stock worth $888,000 after acquiring an additional 16,500 shares during the period. Nationwide Fund Advisors boosted its holdings in shares of Mallinckrodt by 45.6% during the second quarter. Nationwide Fund Advisors now owns 47,405 shares of the company’s stock worth $2,124,000 after acquiring an additional 14,843 shares during the period. Amalgamated Bank boosted its holdings in shares of Mallinckrodt by 157.4% during the second quarter. Amalgamated Bank now owns 19,626 shares of the company’s stock worth $879,000 after acquiring an additional 12,001 shares during the period. Finally, Laurion Capital Management LP bought a new stake in shares of Mallinckrodt in the second quarter valued at approximately $954,000.
TRADEMARK VIOLATION NOTICE: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://stocknewstimes.com/2018/02/11/mallinckrodt-plc-mnk-given-consensus-rating-of-hold-by-analysts.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.